Skip to content

Clinical data analysis of GSM in menopausal and perimenopausa women

Clinical data analysis of GSM in menopausal and perimenopausa women

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096439
Enrollment
Unknown
Registered
2025-01-23
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genitourinary Syndrome of Menopaus (GSM)

Interventions

Sexual symptoms:None
Postmenopausal without GSM:None
Childbearing age without GSM:None
Experimental group A( genital symptoms):None
Experimental group B (urological symptoms):None

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.(Conforming to any of the following): The age of women >=40 years, and FSH>40U/L, after hysterectomy; The age of women >=40 years, and menopause >=12 months;The age of women >=20 and <=40 years,and no GSM symptoms; 2.Women have at least one of the following symptoms. (1) Reproductive tract related symptoms: itching of the vulva or vagina, vaginal dryness, burning pain, repeated abnormal discharge, etc.; (2) Urinary tract related symptoms: frequent urination, urgency, urethral discomfort, increased nocturia, dysuria, repeated urinary tract infections, etc.; (3) Changes in the quality of sexual life: decreased libido, dyspareunia, painful intercourse, etc.

Exclusion criteria

Exclusion criteria: 1. Acute inflammation of the reproductive tract; 2. Using hormone drugs in the past 3 months; 3. Using antibiotics or receiving GSM treatment in the past few months; 4. There are organic lesions such as skin lesions of the vulva, vaginal and cervical intraepithelial neoplasia, urinary tract tumors and stones; 5. In the past 1 month, vaginal drugs and preparations such as moisturizers and lubricants have been used; 6. Suffering from mental system diseases and organic encephalopathy; 7. Combined with chronic diseases affecting treatment compliance; 8. Patients who are participating in other clinical trials; 9. In the past 1 month, there have been cases of vaginal irrigation and other changes in the vaginal microenvironment; 10.Other reasons deemed unsuitable for clinical trials by the investigators.

Design outcomes

Primary

MeasureTime frame
Urinary tract microbiota differences;Vaginal microbiota differences;

Countries

China

Contacts

Public ContactLi Ling

The Second Affiliated Hospital of Chongqing Medical University

525800578@qq.com+86 23 63693501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026